Murat Erdoğan1, Mehmet Köse2, Sevgi Pekcan3, Melih Hangül2, Burhan Balta1, Aslıhan Kiraz1, Gizem Akıncı Gönen1, Ayşe Gül Zamani4, Mahmut Selam Yıldırım4, Tuğba Ramaslı Gürsoy5, Fatih Ezgu6, Tuğba Şişmanlar Eyüpoğlu5, Ayse Tana Aslan5. 1. Department of Medical Genetics, Kayseri Training and Research Hospital, Kayseri, Turkey. 2. Division of Pediatric Pulmonology, Department of Pediatrics, Erciyes University, Kayseri, Turkey. 3. Meram Medicine Faculty, Division of Pediatric Pulmonology, Department of Pediatrics, Necmettin Erbakan University, Konya, Turkey. 4. Meram Medicine Faculty, Department of Medical Genetics, Necmettin Erbakan University, Konya, Turkey. 5. Division of Pediatric Pulmonology, Department of Pediatrics, Gazi University, Ankara, Turkey. 6. Department of Pediatric Metabolic Disorders and Pediatric Genetics, Gazi University, Ankara, Turkey.
Abstract
BACKGROUND: Cystic fibrosis, a pulmonary disease which is an autosomal recessive, inherited, multisystemic genetic disease commonly seen in the Caucasian race, is the most frequent cause of mortality and morbidity. So far, more than 2000 disease-causing gene variants have been found and this number has been increasing with the studies conducted. Although there is not yet enough data that include the Turkish population, the recent increase of studies is noteworthy. AIMS: To discover the genetic variation in patients diagnosed with cystic fibrosis in the Central Anatolian region. STUDY DESIGN: Cross-sectional study. METHODS: The study was carried out in the Central Anatolian region in 3 pediatric pulmonology departments (Kayseri, Konya, and Ankara) in Turkey between July 2014 and December 2017. The Sanger and Next Generation Sequence analyses were used for exon and exon-intron boundaries in the cystic fibrosis transmembrane conductance regulatory (CFTR) gene, and in selected patients, mutation analysis was performed using the Multiplex Ligation-dependent Probe Amplification technique for large deletions and duplications. RESULTS: CFTR gene analysis was performed for 316 patients and 215 of them were genetically diagnosed with cystic fibrosis. Sixtythree different variants were defined in these patients and 7 of these were large deletions/duplications detected with the MLPA method. The most frequent variants were F508del (29.6%), G85E (8.2%), N1303K (8.2%), Y515* (7.5%), and G542* (3.4%). CONCLUSION: Using sequencing and Multiplex Ligation-dependent Probe Amplification methods, the identification of seven new mutations that were not previously reported in the literature contributes to a better understanding of the heterogeneous nature of CFTR mutations in the Turkish population. When no mutations are detected (pathogenic/probably pathogenic) in clinically compatible cases, Multiplex Ligationdependent Probe Amplification analysis contributes significantly to the diagnosis.
BACKGROUND: Cystic fibrosis, a pulmonary disease which is an autosomal recessive, inherited, multisystemic genetic disease commonly seen in the Caucasian race, is the most frequent cause of mortality and morbidity. So far, more than 2000 disease-causing gene variants have been found and this number has been increasing with the studies conducted. Although there is not yet enough data that include the Turkish population, the recent increase of studies is noteworthy. AIMS: To discover the genetic variation in patients diagnosed with cystic fibrosis in the Central Anatolian region. STUDY DESIGN: Cross-sectional study. METHODS: The study was carried out in the Central Anatolian region in 3 pediatric pulmonology departments (Kayseri, Konya, and Ankara) in Turkey between July 2014 and December 2017. The Sanger and Next Generation Sequence analyses were used for exon and exon-intron boundaries in the cystic fibrosis transmembrane conductance regulatory (CFTR) gene, and in selected patients, mutation analysis was performed using the Multiplex Ligation-dependent Probe Amplification technique for large deletions and duplications. RESULTS: CFTR gene analysis was performed for 316 patients and 215 of them were genetically diagnosed with cystic fibrosis. Sixtythree different variants were defined in these patients and 7 of these were large deletions/duplications detected with the MLPA method. The most frequent variants were F508del (29.6%), G85E (8.2%), N1303K (8.2%), Y515* (7.5%), and G542* (3.4%). CONCLUSION: Using sequencing and Multiplex Ligation-dependent Probe Amplification methods, the identification of seven new mutations that were not previously reported in the literature contributes to a better understanding of the heterogeneous nature of CFTR mutations in the Turkish population. When no mutations are detected (pathogenic/probably pathogenic) in clinically compatible cases, Multiplex Ligationdependent Probe Amplification analysis contributes significantly to the diagnosis.
Authors: D Angelicheva; F Calafell; A Savov; A Jordanova; A Kufardjieva; I Galeva; V Nedkova; T Ivanova; P Yankova; D Konstantinova; E Genev; L Kalaydjieva Journal: Hum Genet Date: 1997-04 Impact factor: 4.132
Authors: Deniz Dogru; Erkan Çakır; Tuğba Şişmanlar; Nazan Çobanoğlu; Sevgi Pekcan; Güzin Cinel; Ebru Yalçın; Nural Kiper; Velat Şen; Hadice S Şen; Ömür Ercan; Özlem Keskin; Sevgi B Eltan; Lina M Al Shadfan; Hakan Yazan; Derya U Altıntaş; Şenay Şaşihüseyinoğlu; Nihat Sapan; Şükrü Çekiç; Haluk Çokuğraş; Ayşe A Kılınç; Tuğba R Gürsoy; Ayşe T Aslan; Ayşen Bingöl; Abdurrahman E Başaran; Ali Özdemir; Mehmet Köse; Melih Hangül; Nagehan Emiralioğlu; Gökçen Tuğcu; Hasan Yüksel; Özge Yılmaz; Fazıl Orhan; Zeynep G Gayretli Aydın; Erdem Topal; Zeynep Tamay; Ayşe Süleyman; Demet Can; Cem M Bal; Gönül Çaltepe; Uğur Özçelik Journal: Pediatr Pulmonol Date: 2019-11-11
Authors: Sue Richards; Nazneen Aziz; Sherri Bale; David Bick; Soma Das; Julie Gastier-Foster; Wayne W Grody; Madhuri Hegde; Elaine Lyon; Elaine Spector; Karl Voelkerding; Heidi L Rehm Journal: Genet Med Date: 2015-03-05 Impact factor: 8.822
Authors: Michael S Watson; Garry R Cutting; Robert J Desnick; Deborah A Driscoll; Katherine Klinger; Michael Mennuti; Glenn E Palomaki; Bradley W Popovich; Victoria M Pratt; Elizabeth M Rohlfs; Charles M Strom; C Sue Richards; David R Witt; Wayne W Grody Journal: Genet Med Date: 2004 Sep-Oct Impact factor: 8.822